Who are Vumerity's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tecfidera, Niaspan, Tecfidera, Vumerity, Olbemox, Extended-release niacin (ERN).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/diroximel-fumarate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vumerity — Competitive Intelligence Brief

Vumerity (DIROXIMEL FUMARATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Hydroxycarboxylic acid receptor 2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Vumerity (DIROXIMEL FUMARATE) — Biogen. Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vumerity TARGET	DIROXIMEL FUMARATE	Biogen	marketed		Hydroxycarboxylic acid receptor 2	2019-01-01
Tecfidera	DIMETHYL FUMARATE	Biogen	marketed	dimethyl fumarate	Hydroxycarboxylic acid receptor 2	2013-01-01
Niaspan	Nicotinic Acid	Medpointe Pharm Hlc	marketed	Non-Standardized Food Allergenic Extract [EPC]	Hydroxycarboxylic acid receptor 2	1957-01-01
Tecfidera	Tecfidera	EMD Serono Research & Development Institute, Inc.	marketed		Hydroxycarboxylic acid receptor 2, Kelch-like ECH-associated protein 1
Vumerity	Vumerity	University of Nebraska	marketed		Nuclear factor erythroid 2-related factor 2, Hydroxycarboxylic acid receptor 2
Olbemox	ACIPIMOX		phase 3	acipimox	Hydroxycarboxylic acid receptor 2
Extended-release niacin (ERN)	Extended-release niacin (ERN)	Merck Sharp & Dohme LLC	phase 3	Nicotinic acid derivative / Lipid-modifying agent	GPR109A (hydroxycarboxylic acid receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vumerity — Competitive Intelligence Brief. https://druglandscape.com/ci/diroximel-fumarate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab